XORTX Reminds Shareholders to Vote ahead of the Proxy Voting Deadline for the Company’s Upcoming Annual and Special Meeting of Shareholders
23 Junho 2023 - 9:51PM
XORTX Therapeutics Inc. ("
XORTX" or the
“
Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt:
ANU), a late-stage clinical pharmaceutical company focused on
developing innovative therapies to treat progressive kidney
disease, would like to remind shareholders that they have until
10:00 a.m. (Calgary time) on Monday, June 26, 2023 to vote their
shares for the Company’s upcoming annual and special meeting of
shareholders to be held on Wednesday, June 28, 2023 at 10:00 a.m.
(Calgary time) (the “
Meeting”).
Dr. Allen Davidoff, CEO of XORTX stated, "XORTX
has made substantial advances during the past year guided by our
experienced and skilled R&D team and our broadly experienced
board of directors. As the Company advances our late stage
program in ADPKD toward the start of registration clinical trial
initiation, the Company’s reliance upon our board of directors
individual licensing, partnering and commercialization skills will
increase substantially. Shareholders are encouraged to vote
and support the resolutions being voted at this year’s Meeting to
support a stable process toward licensing deal and the goal of
building a high value company.”
Shareholders are urged to carefully read the
information circular in connection with the Meeting. A copy of the
information circular and all other meeting materials is available
on SEDAR at www.sedar.com and on XORTX’s website at www.xortx.com.
XORTX’s board of directors recommends shareholders vote FOR all of
the proposed resolutions.
YOUR VOTE IS IMPORTANT REGARDLESS OF THE
NUMBER OF SHARES YOU OWN.PLEASE VOTE TODAY. THE
PROXY CUT-OFF IS MONDAY, JUNE 26, 2023AT 10 A.M.
MOUNTAIN TIME.
Shareholder Assistance
Shareholders who have questions, or need assistance with voting
their shares, should contact Laurel Hill Advisory Group, the proxy
solicitation agent, by telephone at +1 877-452-7184 (North America
toll free) or + 1 416-304-0211 (outside North America), or by email
at assistance@laurelhill.com.
About XORTX Therapeutics Inc.
XORTX is a pharmaceutical company with two
clinically advanced products in development: 1) our lead, XRx-008
program for ADPKD; and 2) our secondary program in XRx-101 for
acute kidney and other acute organ injury associated with
Coronavirus / COVID-19 infection. In addition, XRx-225 is a
pre-clinical stage program for Type 2 Diabetic Nephropathy. XORTX
is working to advance its clinical development stage products that
target aberrant purine metabolism and xanthine oxidase to decrease
or inhibit production of uric acid. At XORTX, we are dedicated to
developing medications to improve the quality of life and future
health of patients. Additional information on XORTX is available at
www.xortx.com.
For more information, please contact:
Allen Davidoff, CEOadavidoff@xortx.com or +1 403 455 7727 |
Nick Rigopulos, Director of
Communicationsnick@alpineequityadv.com or +1 617 901 0785 |
|
|
Media Inquiries, David Melamed,
Ph.D.david.melamed@russopartnersllc.com or +1 212 845 4225 |
|
|
Neither the TSX Venture Exchange nor Nasdaq has
approved or disapproved the contents of this news release. No stock
exchange, securities commission or other regulatory authority has
approved or disapproved the information contained herein.
Forward Looking Statements
This press release contains express or implied
forward-looking statements pursuant to U.S. Federal securities
laws. These forward-looking statements and their implications are
based on the current expectations of the management of XORTX only,
and are subject to a number of factors and uncertainties that could
cause actual results to differ materially from those described in
the forward-looking statements. Except as otherwise required by
law, XORTX undertakes no obligation to publicly release any
revisions to these forward-looking statements to reflect events or
circumstances after the date hereof or to reflect the occurrence of
unanticipated events. More detailed information about the risks and
uncertainties affecting XORTX is contained under the heading “Risk
Factors” in XORTX’s Registration Statement on Form F-1 filed with
the SEC, which is available on the SEC's website, www.sec.gov
(including any documents forming a part thereof or incorporated by
reference therein), as well as in our reports, public disclosure
documents and other filings with the securities commissions and
other regulatory bodies in Canada, which are available on
www.sedar.com.
XORTX Therapeutics (NASDAQ:XRTX)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
XORTX Therapeutics (NASDAQ:XRTX)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024